BR0308706A - Hidrato estável de um antagonista de receptor muscarìnico - Google Patents
Hidrato estável de um antagonista de receptor muscarìnicoInfo
- Publication number
- BR0308706A BR0308706A BR0308706-9A BR0308706A BR0308706A BR 0308706 A BR0308706 A BR 0308706A BR 0308706 A BR0308706 A BR 0308706A BR 0308706 A BR0308706 A BR 0308706A
- Authority
- BR
- Brazil
- Prior art keywords
- bladder
- urinary
- receptor antagonist
- muscarinic receptor
- treatment
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title abstract 2
- 239000003149 muscarinic antagonist Substances 0.000 title abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 2
- 206010056948 Automatic bladder Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000012258 Diverticular disease Diseases 0.000 abstract 1
- 206010013554 Diverticulum Diseases 0.000 abstract 1
- 208000000289 Esophageal Achalasia Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010021639 Incontinence Diseases 0.000 abstract 1
- 206010027566 Micturition urgency Diseases 0.000 abstract 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 abstract 1
- 206010029279 Neurogenic bladder Diseases 0.000 abstract 1
- 206010030136 Oesophageal achalasia Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 201000000621 achalasia Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000029162 bladder disease Diseases 0.000 abstract 1
- 206010013990 dysuria Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 201000003890 low compliance bladder Diseases 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000026533 urinary bladder disease Diseases 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"HIDRATO ESTáVEL DE UM ANTAGONISTA DE RECEPTOR MUSCARìNICO". A presente invenção refere-se a um hidrato sólido estável de um antagonista de receptor muscarínico que é útil no tratamento de síndrome de intestino irritável, doença diverticular, acalasia esofageal, doença de vias aéreas obstrutivas crónica, bexiga super ativa incluindo sintomas de incontinência, urgência e freq³ência, incontinência urinária, urgência urinária neurogênica ou polaquiúria, tratamento de distúrbio funcional de bexiga, vazamento urinário, micção difícil ou dolorosa causada por bexiga neurogênica, bexiga hipertónica ou espástica, síndrome de bexiga disfuncional, distúrbios gastrointestinais incluindo hiperatividade gastrointestinal, e efeito relaxante sobre células de músculo liso.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0207104.1 | 2002-03-26 | ||
GBGB0207104.1A GB0207104D0 (en) | 2002-03-26 | 2002-03-26 | Stable hydrate of a muscarinic receptor antagonist |
PCT/IB2003/001043 WO2003080599A1 (en) | 2002-03-26 | 2003-03-17 | Stable hydrate of a muscarinic receptor antagonist |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0308706A true BR0308706A (pt) | 2005-01-04 |
BRPI0308706B1 BRPI0308706B1 (pt) | 2018-07-10 |
BRPI0308706B8 BRPI0308706B8 (pt) | 2021-05-25 |
Family
ID=9933731
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122018000397A BR122018000397B8 (pt) | 2002-03-26 | 2003-03-17 | solvato de darifenacina, e processo para sua preparação |
BRPI0308706A BRPI0308706B8 (pt) | 2002-03-26 | 2003-03-17 | hidrato de darifenacina, e processo para sua preparação |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122018000397A BR122018000397B8 (pt) | 2002-03-26 | 2003-03-17 | solvato de darifenacina, e processo para sua preparação |
Country Status (23)
Country | Link |
---|---|
US (3) | US6930188B2 (pt) |
EP (2) | EP2336124B1 (pt) |
JP (2) | JP2005524678A (pt) |
KR (4) | KR101026283B1 (pt) |
CN (1) | CN100345840C (pt) |
AR (1) | AR042608A1 (pt) |
AT (1) | ATE495169T1 (pt) |
AU (1) | AU2003209921A1 (pt) |
BR (2) | BR122018000397B8 (pt) |
CA (1) | CA2480287C (pt) |
CY (2) | CY1111200T1 (pt) |
DE (1) | DE60335711D1 (pt) |
DK (2) | DK2336124T3 (pt) |
ES (2) | ES2358644T3 (pt) |
GB (1) | GB0207104D0 (pt) |
HK (2) | HK1080847A1 (pt) |
PA (1) | PA8569701A1 (pt) |
PT (2) | PT1490357E (pt) |
SI (2) | SI1490357T1 (pt) |
SV (1) | SV2003001515A (pt) |
TW (1) | TW200306816A (pt) |
UY (1) | UY27735A1 (pt) |
WO (1) | WO2003080599A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0207104D0 (en) * | 2002-03-26 | 2002-05-08 | Pfizer Ltd | Stable hydrate of a muscarinic receptor antagonist |
US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
BRPI0609952A2 (pt) * | 2005-04-24 | 2010-05-11 | Wyeth Corp | métodos para modular a função da bexiga |
EP1966179A2 (en) | 2005-12-27 | 2008-09-10 | Teva Pharmaceutical Industries Ltd | Darifenacin hydrobromide composition substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof |
WO2008100651A2 (en) * | 2007-01-05 | 2008-08-21 | Dr. Reddy's Laboratories Ltd. | Preparation of darifenacin and its salts |
ES2554646T3 (es) * | 2007-02-23 | 2015-12-22 | Theravance Biopharma R&D Ip, Llc | Compuestos de difenilmetilo de amonio cuaternario, de utilidad como antagonistas de receptores muscarínicos |
WO2008144602A1 (en) * | 2007-05-18 | 2008-11-27 | Auspex Pharmaceuticals, Inc. | Deuterated zamifenacin derivatives |
WO2009007853A2 (en) * | 2007-06-08 | 2009-01-15 | Actavis Group Ptc Ehf | Novel polymorphs of darifenacin free base and its hydrobromide salt |
US20090005431A1 (en) * | 2007-06-30 | 2009-01-01 | Auspex Pharmaceuticals, Inc. | Substituted pyrrolidines |
AR068322A1 (es) * | 2007-07-13 | 2009-11-11 | Medichem Sa | Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion |
CZ200845A3 (cs) | 2008-01-28 | 2009-09-02 | Zentiva, A. S. | Zpusob prípravy Darifenacinu |
WO2009125426A2 (en) * | 2008-02-08 | 2009-10-15 | Neuland Laboratories Ltd | NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE |
JP5450387B2 (ja) | 2008-04-02 | 2014-03-26 | 株式会社カネカ | (s)−3−(1−シアノ−1,1−ジフェニルメチル)−ピロリジンの製造法 |
US20110144354A1 (en) * | 2008-09-22 | 2011-06-16 | Watson Pharma Private Limited | Process for Preparation of Darifenacin and Intermediates Used in the Process |
EP2236509A1 (en) | 2009-04-01 | 2010-10-06 | Ragactives, S.L. | Method for obtaining 1,3-difunctionalized pyrrolidine derivatives |
WO2011070419A1 (en) | 2009-12-10 | 2011-06-16 | Aurobindo Pharma Limited | An improved process for the preparation of darifenacin hydrobromide |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EA201891416A1 (ru) * | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
CN109641822B (zh) * | 2016-08-12 | 2022-03-11 | 拜耳作物科学股份公司 | 制备取代苯乙烯衍生物的方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8906166D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
US5233053A (en) * | 1989-03-17 | 1993-08-03 | Pfizer Inc. | Pyrrolidine derivatives |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9400600D0 (en) | 1994-01-14 | 1994-03-09 | Pfizer Ltd | Treatment of motion seckness |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
GB9612710D0 (en) * | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
KR20010029519A (ko) * | 1996-09-19 | 2001-04-06 | 이곤 이 버그 | 요실금 치료 방법 |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
GB0207104D0 (en) * | 2002-03-26 | 2002-05-08 | Pfizer Ltd | Stable hydrate of a muscarinic receptor antagonist |
-
2002
- 2002-03-26 GB GBGB0207104.1A patent/GB0207104D0/en not_active Ceased
-
2003
- 2003-03-17 KR KR1020047015243A patent/KR101026283B1/ko active IP Right Grant
- 2003-03-17 EP EP10177716A patent/EP2336124B1/en not_active Expired - Lifetime
- 2003-03-17 CN CNB038070847A patent/CN100345840C/zh not_active Expired - Lifetime
- 2003-03-17 AU AU2003209921A patent/AU2003209921A1/en not_active Abandoned
- 2003-03-17 BR BR122018000397A patent/BR122018000397B8/pt not_active IP Right Cessation
- 2003-03-17 WO PCT/IB2003/001043 patent/WO2003080599A1/en active Application Filing
- 2003-03-17 PT PT03744716T patent/PT1490357E/pt unknown
- 2003-03-17 JP JP2003578353A patent/JP2005524678A/ja not_active Withdrawn
- 2003-03-17 ES ES03744716T patent/ES2358644T3/es not_active Expired - Lifetime
- 2003-03-17 PT PT101777167T patent/PT2336124E/pt unknown
- 2003-03-17 CA CA2480287A patent/CA2480287C/en not_active Expired - Lifetime
- 2003-03-17 KR KR1020117027931A patent/KR101212908B1/ko active IP Right Grant
- 2003-03-17 DK DK10177716.7T patent/DK2336124T3/da active
- 2003-03-17 KR KR1020107018853A patent/KR20100101182A/ko not_active Application Discontinuation
- 2003-03-17 DE DE60335711T patent/DE60335711D1/de not_active Expired - Lifetime
- 2003-03-17 KR KR1020127018787A patent/KR20120098888A/ko not_active Application Discontinuation
- 2003-03-17 SI SI200331973T patent/SI1490357T1/sl unknown
- 2003-03-17 ES ES10177716T patent/ES2394067T3/es not_active Expired - Lifetime
- 2003-03-17 SI SI200332215T patent/SI2336124T1/sl unknown
- 2003-03-17 EP EP03744716A patent/EP1490357B1/en not_active Expired - Lifetime
- 2003-03-17 AT AT03744716T patent/ATE495169T1/de active
- 2003-03-17 BR BRPI0308706A patent/BRPI0308706B8/pt not_active IP Right Cessation
- 2003-03-17 DK DK03744716.6T patent/DK1490357T3/da active
- 2003-03-20 PA PA20038569701A patent/PA8569701A1/es unknown
- 2003-03-24 AR ARP030101017A patent/AR042608A1/es unknown
- 2003-03-25 US US10/396,887 patent/US6930188B2/en not_active Expired - Lifetime
- 2003-03-25 TW TW092106635A patent/TW200306816A/zh unknown
- 2003-03-25 SV SV2003001515A patent/SV2003001515A/es not_active Application Discontinuation
- 2003-03-25 UY UY27735A patent/UY27735A1/es not_active Application Discontinuation
-
2005
- 2005-07-13 US US11/180,433 patent/US20050245597A1/en not_active Abandoned
-
2006
- 2006-01-18 HK HK06100807A patent/HK1080847A1/xx not_active IP Right Cessation
-
2008
- 2008-03-17 US US12/049,660 patent/US7696357B2/en not_active Expired - Lifetime
-
2010
- 2010-06-02 JP JP2010126865A patent/JP2010195828A/ja active Pending
-
2011
- 2011-02-22 CY CY20111100213T patent/CY1111200T1/el unknown
- 2011-10-17 HK HK11111039.7A patent/HK1156626A1/xx not_active IP Right Cessation
-
2012
- 2012-11-29 CY CY20121101165T patent/CY1113433T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0308706A (pt) | Hidrato estável de um antagonista de receptor muscarìnico | |
BRPI0509298A (pt) | composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto | |
WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
WO2008002621A3 (en) | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | |
WO2006023460A3 (en) | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | |
MA31004B1 (fr) | Dispersion solide d'un antagoniste de la neurokinine | |
MA31289B1 (fr) | Derives de thiazolidine | |
BRPI0512418A (pt) | derivado de pirrolpirimidina ou pirrolpiridina substituìdo com um grupo amino cìclico, compostos, antagonista para receptores de crf, uso de um derivado de pirrolpirimidina ou pirrolpiridina substituìdo com um grupo amino cìclico, de um sal do mesmo e de seu hidrato farmaceuticamente aceitáveis | |
US20060173052A1 (en) | Use of the non-opiate analgesic drug flupirtine of the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome | |
MX2009009320A (es) | Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora. | |
BRPI0618383A2 (pt) | derivados de 3-aril-isoxazol-4-carbonil-benzofurano | |
WO2006104870A3 (en) | Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors | |
CO6341624A2 (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
DE602005000676D1 (de) | Triazacyclopentaäcdüindenderivate | |
Cardelús et al. | Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle | |
EA200800071A1 (ru) | Производные бензофуранила как ингибиторы 5-нт6-рецептора | |
WO2009117283A3 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
WO2006038611A1 (ja) | 下部尿路閉塞疾患に伴う蓄尿障害の予防及び/又は治療剤 | |
WO2002083074A3 (en) | Methods for the treatment of hepatic disorders | |
DOP2003000615A (es) | Hidrato estable de un antagonista de receptores muscarinicos | |
WO2007051007A3 (en) | Combination of antihypertensives with cholesterol-lowering agent | |
WO2005118537A3 (en) | Arylpiperazine derivatives as adrenergic receptor antagonists | |
RU2010115647A (ru) | Композиция и способ лечения или профилактики доброкачественной гиперплазии предстательной железы и симптомов со стороны нижних отделов мочевыводящих путей | |
PL2020234T3 (pl) | Synergiczne połączenie bromku pinaweryny i dimetikonu lub simetikonu | |
EA201000440A1 (ru) | Способ лечения центральной нервной системы и беспорядочных болей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: ASPEN GLOBAL INCORPORATED (MR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: ASPEN GLOBAL INCORPORATED (MR) |
|
B65X | Notification of requirement for priority examination of patent application | ||
B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B17A | Notification of administrative nullity (patentee has 60 days time to reply to this notification) |
Free format text: REQUERENTE DA NULIDADE: ZODIAC PRODUTOS FARMACEUTICOS S.A. - PETICAO NO870190002945 DE 10/01/2019. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 17/03/2023 |